Luspatercept
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB12281 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 23 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | monosomy X | KG + DL |
| 2 | hepatic infarction | KG + DL |
| 3 | hepatic veno-occlusive disease | KG + DL |
| 4 | peliosis hepatis | KG + DL |
| 5 | syndrome with combined immunodeficiency | KG + DL |
| 6 | pyruvate kinase deficiency of red cells | KG + DL |
| 7 | thalassemia, beta+, silent allele | KG + DL |
| 8 | familial apolipoprotein C-II deficiency | KG + DL |
| 9 | adenosine deaminase deficiency | KG + DL |
| 10 | Hb Bart’s hydrops fetalis | KG + DL |
| 11 | beta-thalassemia with other manifestations | KG + DL |
| 12 | mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies | KG + DL |
| 13 | partial deletion of the short arm of chromosome 16 | KG + DL |
| 14 | hemolytic anemia due to glucophosphate isomerase deficiency | KG + DL |
| 15 | liver angiosarcoma | KG + DL |
| 16 | pyropoikilocytosis, hereditary | KG + DL |
| 17 | reticular dysgenesis | KG + DL |
| 18 | severe combined immunodeficiency due to LCK deficiency | KG + DL |
| 19 | exocrine pancreatic insufficiency | KG + DL |
| 20 | hereditary persistence of fetal hemoglobin-beta-thalassemia syndrome | KG + DL |
| 21 | spherocytosis | KG + DL |
| 22 | extrahepatic biliary atresia | KG + DL |
| 23 | acute erythroid leukemia | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.